TY - JOUR
T1 - The European Academy of Neurology COVID-19 registry (ENERGY)
T2 - an international instrument for surveillance of neurological complications in patients with COVID-19
AU - for the EAN Neuro-COVID Task Force
AU - Beghi, Ettore
AU - Helbok, Raimund
AU - Crean, Michael
AU - Chou, Sherry Hsiang Yi
AU - McNett, Molly
AU - Moro, Elena
AU - Bassetti, Claudio
AU - Jenkins, Tom
AU - Oertzen, Tim
AU - Bodini, Benedetta
AU - Marcerollo, Antonella
AU - Rakusa, Martin
AU - Soffietti, Riccardo
AU - Oreja-Guevara, Celia
AU - Bereczki, Daniel
AU - Ozturk, Serefnur
AU - Pisani, Antonio
AU - Sellner, Johann
AU - Taba, Pille
AU - Diliberto, Giovanni
AU - Leys, Didier
AU - Sauerbier, Anna
AU - Cavallieri, Francesco
AU - Priori, Alberto
AU - Zedde, Marialuisa
N1 - Publisher Copyright:
© 2020 European Academy of Neurology.
PY - 2021/10
Y1 - 2021/10
N2 - The COVID-19 pandemic is a global public health issue. Neurological complications have been reported in up to one-third of affected cases, but their distribution varies significantly in terms of prevalence, incidence and phenotypical characteristics. Variability can be mostly explained by the differing sources of cases (hospital vs. community-based), the accuracy of the diagnostic approach and the interpretation of the patients’ complaints. Moreover, after recovering, patients can still experience neurological symptoms. To obtain a more precise picture of the neurological manifestations and outcome of the COVID-19 infection, an international registry (ENERGY) has been created by the European Academy of Neurology in collaboration with European national neurological societies and the Neurocritical Care Society and Research Network. ENERGY can be implemented as a stand-alone instrument for patients with suspected or confirmed COVID-19 and neurological findings or as an addendum to an existing registry not targeting neurological symptoms. Data are also collected to study the impact of neurological symptoms and neurological complications on outcomes. The variables included in the registry have been selected in the interests of most countries, to favour pooling with data from other sources and to facilitate data collection even in resource-poor countries. Included are adults with suspected or confirmed COVID-19 infection, ascertained through neurological consultation, and providing informed consent. Key demographic and clinical findings are collected at registration. Patients are followed up to 12 months in search of incident neurological manifestations. As of 19 August, 254 centres from 69 countries and four continents have made requests to join the study.
AB - The COVID-19 pandemic is a global public health issue. Neurological complications have been reported in up to one-third of affected cases, but their distribution varies significantly in terms of prevalence, incidence and phenotypical characteristics. Variability can be mostly explained by the differing sources of cases (hospital vs. community-based), the accuracy of the diagnostic approach and the interpretation of the patients’ complaints. Moreover, after recovering, patients can still experience neurological symptoms. To obtain a more precise picture of the neurological manifestations and outcome of the COVID-19 infection, an international registry (ENERGY) has been created by the European Academy of Neurology in collaboration with European national neurological societies and the Neurocritical Care Society and Research Network. ENERGY can be implemented as a stand-alone instrument for patients with suspected or confirmed COVID-19 and neurological findings or as an addendum to an existing registry not targeting neurological symptoms. Data are also collected to study the impact of neurological symptoms and neurological complications on outcomes. The variables included in the registry have been selected in the interests of most countries, to favour pooling with data from other sources and to facilitate data collection even in resource-poor countries. Included are adults with suspected or confirmed COVID-19 infection, ascertained through neurological consultation, and providing informed consent. Key demographic and clinical findings are collected at registration. Patients are followed up to 12 months in search of incident neurological manifestations. As of 19 August, 254 centres from 69 countries and four continents have made requests to join the study.
KW - COVID-19
KW - EAN
KW - SARS-CoV-2
KW - complications
KW - neurological diseases
KW - outcome
KW - registry
UR - http://www.scopus.com/inward/record.url?scp=85099052103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099052103&partnerID=8YFLogxK
U2 - 10.1111/ene.14652
DO - 10.1111/ene.14652
M3 - Article
C2 - 33220127
AN - SCOPUS:85099052103
SN - 1351-5101
VL - 28
SP - 3303
EP - 3323
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 10
ER -